Windlas Biotech Limited IPO
Windlas Biotech Limited IPO is listed on BSE and NSE, priced at ₹448–₹460 per share. The stock debuted at ₹437. The IPO had a lot size of ₹30 shares and a minimum investment of ₹13,800.
Windlas Biotech Limited IPO
- IPO Dates
- Aug 4, 2021 – Aug 6, 2021
- Price band
- ₹448-460 per equity share
- Minimum Investment
- ₹13,800
- Issue size
- ₹401.53 Crores Total : ₹ 165 Crore Fresh + 236.53 Crore OFS of 51,42,067 Shares
- Lot size
- 30
- Allotment Date
- Aug 11, 2021
- Listing
- Aug 16, 2021
- Listing At
- BSE, NSE
IPO timeline
-
Aug 4, 2021
Open Date
Completed
-
Aug 6, 2021
Close Date
Completed
-
Aug 11, 2021
Allotment Date
Completed
-
Aug 16, 2021
Listing Date
Completed
Price Summary
- Last closing
- 763.00 (65.87%)
- 52 week high
- 1,097.90
- 52 week low
- 697.40
- Last update
Windlas Biotech Limited IPO Essentials
Windlas Biotech Limited IPO Details
Windlas Biotech Limited IPO is priced at ₹448-460 per share with a total issue size of ₹401.53 Crores Total : ₹ 165 Crore Fresh + 236.53 Crore OFS of 51,42,067 Shares. The IPO has a lot size of 30 shares and is listed on BSE and NSE.
- Issue price
- ₹448-460 per equity share
- Lot size
- 30 shares
- Face value
- ₹5 Per Equity Share
- Issue size
- ₹401.53 Crores Total : ₹ 165 Crore Fresh + 236.53 Crore OFS of 51,42,067 Shares
- Listing at
- BSE, NSE
- List price
- 437 (NSE)
- Listing date
- Registrar
- Link Intime India Private Limited
- Lead manager
-
SBI Capital Markets Limited, DAM Capital Advisors Limited, IIFL Securities Limited
Windlas Biotech Limited IPO Analytics
Windlas Biotech Limited IPO category-wise subscription trends show day-wise participation across QIB, NII, and retail investors.
Windlas Biotech Limited IPO Subscription Status
Windlas Biotech Limited IPO subscription status shows demand across retail, NII, and QIB categories, helping investors understand overall participation trends.
The IPO subscription status indicates investor demand across categories.
| As on | QIB |
NII
|
Retail | Total |
|---|---|---|---|---|
| Shares Offered / Reserved | 17,45,804 |
13,09,354
|
30,55,159 | 61,10,317 |
|
Day 1
04-08-21 05:00 PM
|
0.00 x |
0.34x
|
6.22 x | 3.18 x |
|
Day 2
05-08-21 05:00 PM
|
0.04 x |
1.11x
|
13.40 x | 7.00 x |
|
Day 3
06-08-21 08:00 PM
|
24.10 x |
15.91x
|
24.27 x | 22.47 x |
|
Total No. of Applications
|
category wise applications | ||
|---|---|---|---|
| 2089000 (Approx) | 20.51 | ||
Windlas Biotech Limited Valuations
Earnings
- EPS (Post IPO)
- ₹7.17/-
- P/E Ratio
- 64.17
Returns
- RoNW
- 18.19%
Windlas Biotech Limited Financials( In Crs.)
| 31-Mar-21 | 31-Mar-20 | 31-Mar-19 | 31-Mar-18 | |
|---|---|---|---|---|
| Assets | 296.12 | 338.48 | 198.18 | 298.88 |
| Revenue | 430.69 | 331.33 | 311.52 | 356.57 |
| Profit After Tax | 15.57 | 16.21 | 63.82 | 11.19 |
Windlas Biotech Limited Company & Offer Insights
About Windlas Biotech Limited
Windlas Biotech Ltd is one of the leading companies in the pharmaceutical formulations contract development and manufacturing organizations (CDMO) segment in India. The company offers a range of CDMO services from product discovery to product development, licensing, and commercial manufacturing of generic products including complex generics.
It further sells its own branded products in the trade generics and OTC markets. Currently, the focus of the company is to launch complex generic products in the chronic therapeutic category related to lifestyle-related disorders. The business operates in 3 verticals; 1. CDMO Products and services, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and health supplement products), and 3. Export.
Leading pharma companies i.e. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are some of the marquee customers of Windlas Biotech. Its manufacturing facility is located at Dehradun with an installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouch/ sachet, and 61.08 million liquid bottles.
Windlas Biotech Limited Promoter(s)
Ashok Kumar Windlass, Hitesh Windlass, Manoj Kumar Windlass, AKW WBL Family Pvt Trust are the company's promoters of Windlas Biotech Limited.
Windlas Biotech Limited IPO Issue Objectives
- •
- Purchase of equipment required for (i) capacity expansion of our existing facility at Dehradun Plant – IV; and (ii) addition of injectables dosage capability at our existing facility at Dehradun Plant-II;
- •
- General Corporate Purpose
- •
- To meet issue expenses
- •
- Repayment/prepayment of certain of our borrowings
Windlas Biotech Limited IPO - Anchor Investors
Windlas Biotech mobilises Rs 120.46 crore from 22 anchor investors ahead of IPO
Marquee investors who participated in the anchor book were Macquarie, Optimix Wholesale Global Emerging Markets, Invesco Trustee, Kuber India Fund, and Elara India Opportunities Fund.
Among others, ICICI Prudential, Nippon India, UTI MF, Sundaram MF, BNP Paribas, Avendus MF, and Canara HSBC also invested in the company
Contact Information
Frequently Asked Questions
Click any question to reveal the answer
Windlas Biotech Limited IPO is a book-built IPO worth ₹401.53 Crores Total : ₹ 165 Crore Fresh + 236.53 Crore OFS of 51,42,067 Shares. The price band is ₹448–₹460 per share. The IPO opens on Aug 4, 2021 and closes on Aug 6, 2021. It will be listed on BSE and NSE. Link Intime India Private Limited is the registrar.
The price band of Windlas Biotech Limited IPO is ₹448 to ₹460 per share.
The lot size of Windlas Biotech Limited IPO is 30 shares.
The minimum investment for Windlas Biotech Limited IPO is approximately ₹13,800 based on the upper price band .
Windlas Biotech Limited IPO opens on Aug 4, 2021 and closes on Aug 6, 2021.
The allotment date of Windlas Biotech Limited IPO is Aug 11, 2021.
Windlas Biotech Limited IPO is expected to be listed on Aug 16, 2021, on BSE and NSE .
Windlas Biotech Limited IPO listed on Aug 16, 2021. It was issued at ₹437 (NSE) and is currently around ₹763.00 as on 14-May-2026 3:30 PM, which is approximately 65.9% versus issue price. The 52-week high is ₹1,097.90.
Based on listing and post-listing performance, Windlas Biotech Limited IPO delivered around 65.9% over issue price. Whether it was worth applying depends on your risk profile, allocation, and holding horizon.
To buy Windlas Biotech Limited IPO shares after listing, log in to your broker app (such as Zerodha, Angel One, Groww, Upstox, ICICI Direct), search the stock symbol, place a delivery/CNC order, and confirm quantity and price.
Windlas Biotech Limited IPO valuation snapshot: P/E 64.17, EPS ₹7.17/-, P/B N/A, RoNW 18.19%, and market cap N/A.
To apply for Windlas Biotech Limited IPO, open the IPO Ji app or website, select the IPO, choose your demat account, enter the quantity, and submit the application.
You can check the live subscription status of Windlas Biotech Limited IPO on IPO Ji or stock exchange websites. It shows real-time demand across retail, NII, and QIB categories.
Pre-apply allows investors to submit their IPO application before the bidding period starts. The order is placed automatically when the IPO opens.
If you pre-apply for Windlas Biotech Limited IPO, your order will be placed when the IPO bidding starts, and a UPI mandate request will be generated.
You can check Windlas Biotech Limited IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Windlas Biotech Limited IPO allotment status on IPO Ji for quick and easy access.